Beam Therapeutics (BEAM) Is Up 20.6% After Positive Gene-Editing Data And New Credit Facility - Has The Bull Case Changed? [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
deficiency, while also securing a US$500 million credit facility from Sixth Street to support an anticipated commercial launch. Amid these clinical and financing milestones, CEO John Evans sold just over 30,000 shares under a pre-arranged plan but retained more than 1.04 million shares, signalling continued direct exposure to the company's progress. Next, we'll examine how the positive Phase 1/2 results could reshape Beam Therapeutics' investment narrative and long-term opportunity. Outshine the giants: these 19 early-stage AI stocks could fund your retirement Beam Therapeutics Investment Narrative Recap To own Beam Therapeutics, you need to believe base editing can translate early clinical signals in sickle cell disease and alpha 1 antitrypsin deficiency into approved therapies, despite safety, competition and funding risks. The latest Phase 1/2 data and new US$500 million credit facility appear to reinforce the near term catalyst around risto cel's potential path to market
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics (BEAM): Among the Stocks That Could 10x Over the Next 5 Years [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of MedicineGlobeNewswire
- How The Investment Story For Beam Therapeutics (BEAM) Is Quietly Shifting With New Data And Funding [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (BEAM) had its price target raised by Citigroup Inc. from $64.00 to $68.00. They now have a "buy" rating on the stock.MarketBeat
BEAM
Earnings
- 2/24/26 - Beat
BEAM
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- BEAM's page on the SEC website